Search
Zymeworks Inc
ZYMEAdd to Watchlist
21.940USD
-0.770-3.39%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.57BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Zymeworks Inc is 8.57, ranking 99 out of 385 in the Biotechnology & Medical Research industry. The average price target is 33.50, with a high of 42.00 and a low of 25.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
39.333
Target Price
+79.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Zymeworks Inc
ZYME
12
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Kymera Therapeutics Inc
KYMR
24
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Zymeworks Inc's expected revenue for the next quarter?
Zymeworks Inc's expected revenue is 18.01M.
What is Zymeworks Inc's price target?
Analysts forecast that Zymeworks Inc's price target is USD 33.50, with the highest forecast at USD 42.00 and the lowest forecast at USD 25.00.
How have Zymeworks IncZYME's recent earnings per share performed?
The market expectation was USD -0.59, while Zymeworks IncZYME's earnings per share (EPS) for the previous quarter was USD -0.55. EPS for the next quarter is expected at USD -0.46.
What is the analyst rating for Zymeworks Inc?
Based on the ratings of Zymeworks Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.